Pharmacokinetic/Pharmacodynamic Analysis of Standard- and High-Dose Rifampicin to Predict Safety, Completion, and Tolerability of Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial

Background Rifampicin-based tuberculosis preventive therapy (TPT) may shorten treatment duration, but substantial interindividual pharmacokinetic variability may lead to different safety and tolerability profiles at the same dose. We performed pharmacokinetic/pharmacodynamic analyses of standard- and high-dose rifampicin to predict safety, completion, and tolerability. Methods We analyzed data from 1,368 adults and adolescents enrolled in the 2R2 trial comparing two months of rifampicin at 20 or 30 mg/kg/day with four months at 10 mg/kg/day. A population pharmacokinetic model developed from 440 participants was used to predict rifampicin exposure for all participants. Missing exposure metrics were imputed using 1,000 simulated datasets. Exposure-response relationships were evaluated using multivariable logistic regression models fitted within imputed datasets, with coefficients and standard errors pooled across imputations. Results A two-fold increase in total rifampicin exposure (AUC0-24) was associated with higher odds of protocol-defined adverse events (AEs) requiring permanent discontinuation (aOR 1.88, 95% CI 1.25−2.81), discontinuation unrelated to AEs (aOR 1.42, 95% CI 1.15−1.75), and tolerability symptoms potentially related to AEs without discontinuation (aOR 1.48, 95% CI 1.18−1.86); similar patterns were observed for peak concentration (Cmax). Higher AUC0-24 and Cmax were also associated with grade 1−2 and grade 3−4 AEs, rash/allergy/hypersensitivity, gastrointestinal intolerance, and early discontinuation, with no significant association for hepatotoxicity. Exposure-based models showed slightly better discriminatory performance than dose-based models in predicting safety. Conclusion Higher rifampicin exposure was associated with worse safety, completion, and tolerability in TPT. Larger efficacy trials are needed to determine the optimal dose to achieve sufficient exposure, alongside investigation of therapeutic drug monitoring to avoid excessive exposure.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2026-11-19
DOI
https://doi.org/10.1093/cid/ciag647
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacokinetic/Pharmacodynamic Analysis of Standard- and High-Dose Rifampicin to Predict Safety, Completion, and Tolerability of Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial

Eri Flores, Vycke Yunivita, Elin M. Svensson, Federica Fregonese et al.
Clinical Infectious Diseases
Tuberculosis Research and Epidemiology
article

Pharmacokinetic/Pharmacodynamic Analysis of Standard- and High-Dose Rifampicin to Predict Safety, Completion, and Tolerability of Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial

Eri Flores, Vycke Yunivita, Elin M. Svensson, Federica Fregonese, Fajri Gafar, Richard Long, Victor Chiang, Hoa Binh Nguyen, James Cameron Johnston, Greg James Fox, Dick Menzies, Diana Gibson, Rob E. Aarnoutse, Rovina Ruslami, Leila Barss, Lika Apriani, Andrea Benedetti, Dina Fisher, Thu Anh Nguyen, Rachel K Lim, 2R trial investigators, Catherine Paulsen, Nancy Bedingfield, Victoria J Cook, Nguyen Viet Nhung
article en

Abstract

Background Rifampicin-based tuberculosis preventive therapy (TPT) may shorten treatment duration, but substantial interindividual pharmacokinetic variability may lead to different safety and tolerability profiles at the same dose. We performed pharmacokinetic/pharmacodynamic analyses of standard- and high-dose rifampicin to predict safety, completion, and tolerability. Methods We analyzed data from 1,368 adults and adolescents enrolled in the 2R2 trial comparing two months of rifampicin at 20 or 30 mg/kg/day with four months at 10 mg/kg/day. A population pharmacokinetic model developed from 440 participants was used to predict rifampicin exposure for all participants. Missing exposure metrics were imputed using 1,000 simulated datasets. Exposure-response relationships were evaluated using multivariable logistic regression models fitted within imputed datasets, with coefficients and standard errors pooled across imputations. Results A two-fold increase in total rifampicin exposure (AUC0-24) was associated with higher odds of protocol-defined adverse events (AEs) requiring permanent discontinuation (aOR 1.88, 95% CI 1.25−2.81), discontinuation unrelated to AEs (aOR 1.42, 95% CI 1.15−1.75), and tolerability symptoms potentially related to AEs without discontinuation (aOR 1.48, 95% CI 1.18−1.86); similar patterns were observed for peak concentration (Cmax). Higher AUC0-24 and Cmax were also associated with grade 1−2 and grade 3−4 AEs, rash/allergy/hypersensitivity, gastrointestinal intolerance, and early discontinuation, with no significant association for hepatotoxicity. Exposure-based models showed slightly better discriminatory performance than dose-based models in predicting safety. Conclusion Higher rifampicin exposure was associated with worse safety, completion, and tolerability in TPT. Larger efficacy trials are needed to determine the optimal dose to achieve sufficient exposure, alongside investigation of therapeutic drug monitoring to avoid excessive exposure.

Clinical Infectious Diseases
Uppsala University (SE), The University of Sydney (AU), New South Wales Department of Health (AU), University of British Columbia (CA), Radboud University Nijmegen (NL), University of Alberta (CA), University of Calgary (CA), Woolcock Institute of Medical Research (AU), McGill University Health Centre (CA), Radboud University Medical Center (NL), BC Centre for Disease Control (CA), Radboud Institute for Molecular Life Sciences (NL), Hanoi Lung Hospital (VN), Research Institute of the McGill University Health Centre (CA), Montreal Chest Institute (CA), McGill University (CA), Padjadjaran University (ID)
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon